Disaccharidase Activity Panel
Test in Focus
Mayo Clinic Labs’ new disaccharidase activity panel measures levels of five naturally occurring digestive enzymes to detect deficiencies that affect carbohydrate absorption. The panel, as explained by Mayo Clinic pediatric gastroenterologist Pua Hopson, D.O., in this episode of the "Answers From the Lab" podcast, is the gold standard for diagnosing disaccharidase deficiencies, which can cause chronic conditions like celiac disease.
“Oftentimes when we see these patients who have had chronic illness and have chronic symptoms going on for such a long time, it’s hard to piece together the history,” says Dr. Hopson. “It can be quite complex to tease out ‘A causes B.’ In doing an endoscopy the addition of this test may be really beneficial if you find a deficiency, and sometimes can provide a lot of clarity for your patients’ symptoms.”
Dr. Hopson explains that in the proper clinical setting, disaccharidase activity testing can increase disaccharidase disorder identification by 10% to 20%. “In these cases, you’ll have a higher chance of detecting abnormalities and overall helping your patients clinically.”
Listen to learn more about how disaccharidase activity testing improves patient outcomes by equipping providers with specific details about patients’ malabsorption disorders to confirm diagnosis and inform treatment choices.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluation of patients who present with signs or symptoms suggestive of disaccharidase disorders. This test is not intended for carrier detection.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.
Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just one stool sample.